Equities can experience sharp downward price corrections due to various catalysts, including disappointing quarterly earnings reports, downward revisions to forward revenue guidance, sector-wide market sell-offs, or regulatory hurdles. For clinical-stage or small-cap biotechnology and technology enterprises, drops frequently occur secondary to capital-raising dilutions, delayed clinical milestones, or broader risk-off shifts among institutional investors away from high-beta, cash-burning equities.